However, approximately 95% of CRC patients do not respond to PD-1/PD-L1 blockade therapy due to the tumor immunosuppressive microenvironment; thus, only a subset of CRC patients can benefit from it [14, 15]. This evidence concerns the gene PDCD1 and colorectal carcinoma.